Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage Resolution Reshapes Weight Loss Medication…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists Compounded Options Alongside New FDA-Approved…
Sprout Health Serves as Case Study for Provider Model Structure, Program Costs, and FDA-vs-Compounded Disclosure StandardsOrlando, Dec. 26, 2025 (GLOBE…
"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within the timelines required by law,…
WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology follower into an increasingly influential…
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on…
Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…
Platform Analysis: Injectable vs. Dissolving Tablet Formats, Prescription Requirements, Monthly Subscription Costs, and Timeline Expectations for Growth Hormone Secretagogue TherapyAUSTIN,…